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ABSTRACT 
Prochlorperazine dimaleate (also known as Prochlorperazin, Compazine, Capazine, Stemetil, PCZ), the dimaleate salt of Prochlorperazine, is a 
dopamine (D2) receptor antagonist that belongs to the phenothiazine class of antipsychotic agents that are used for the antiemetic treatment of 
nausea and vertigo. It is also a highly potent typical antipsychotic, 10-20 times more potent than chlorpromazine. Prochlorperazine dimaleate is 
also used to treat migraine headaches.  The concept of formulating fast dissolving tablets containing PCZ offers a suitable and practical 
approach in serving desired objective of faster disintegration and dissolution characteristics with increased bioavailability . Fast dissolving 
tablets of PCZ were prepared by direct compression methods and blend was evaluated for the pre-compression parameters such as bulk 
density, compressibility, angle of repose etc. The tablets were prepared by using crosscarmellose sodium, crospovidone and so dium starch 
glycolate, as super disintegrants in different concentration along with microcrystalline cellulose. Total six formulations were prepared and 
evaluated for hardness, friability, weight variation, content uniformity, wetting time, water absorption ratio, disintegration time and invitro 
drug release. In-vitro dissolution studies are performed by using 6.8PH buffer at 50 rpm by paddle method. Overall, the formulation 
F5containing of CP was found to be promising and has shown a disintegration time 65 sec. The stability studies were performed for two months 
(accelerated studies) as per ICH guidelines. The optimized formulation (F5) showed no significant variations for the tablets parameters and it 
was stable for the specified time period. Thus results conclusively demonstrated successful masking of taste and fastest disintegration of the 
formulated tablets in oral cavity. 
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INTRODUCTION 
Many patients find it difficult to swallow tablets and hard 
gelatin capsules and thus do not comply with prescription, 
which results in high incidence of non-compliance and 
ineffective therapy. It is estimated that 70% of the 
population is affected by this problem [1]. Recent advances 
in novel drug delivery systems (NDDS) aimed to enhance 
safety and efficacy of drug molecule by formulating a 
convenient dosage form for administration and to achieve 
better patient compliance. One such approach is fast 
dissolving tablets (FDT) [1-4]. PCZ is a phenothiazine 
antipsychotic and widely used in prevention and treatment 
of nausea, vomiting including that associated with migraine 
or drug-induced emesis [5]. The concept of formulating fast 
dissolving tablets containing PCZ offers a suitable and 
practical approach in serving desired objective of faster 
disintegration and dissolution characteristics with increased 
bioavailability by simple and cost effective direct 
compression technique. Upon ingestion, the saliva serves to 
rapidly disperse/dissolve the dosage form. The saliva 
containing the dissolved/dispersed medicament is then 
swallowed and the drug is absorbed in the normal way. Some 
drugs are absorbed from mouth, pharynx and esophagus as 
the saliva passes down into the stomach [6]. In such cases, 
bioavailability is significantly greater than those observed 
from conventional dosage form. In present study an attempt 
has been made to formulate the orally disintegrating tablets 
by direct compression method using sodium starch glycolate, 
crosscarmellose sodium and crospovidone as the 
superdisintegrants for rapid dissolution of drug and 
absorption, which may produce the rapid onset of action. 
MATERIALS AND METHODS 
Materials 
Prochlorperazine dimaleate was purchased from Sigma 
Aldrich-Merck, Bengaluru, Karnataka, India. Crospovidone, 
sodium starch glycolate and sodium starch glycolate was 
obtained from Hi-Media Laboratories Pvt. Ltd., Mumbai, 
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India. Micro crystalline cellulose, mannitol, talc and 
magnesium stearate was procured from Central Drug House 
(P) Ltd. New Delhi. All other solvents and chemicals used 
were of analytical grade. 
Methods 
Preformulation studies 
Standardization of PCZ by UV-Visible spectrophotometry 
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
phosphate buffer pH 6.8 solutions in 10 ml of volumetric 
flask. The resulted solution 1000µg/ml and from this 
solution 1 ml pipette out and transfer into 10 ml volumetric 
flask and volume make up with phosphate buffer pH 6.8 
solution prepare suitable dilution to make it to a 
concentration range of 2-10μg/ml. The spectrum of this 
solution was run in 200-400 nm range in U.V. 
spectrophotometer (Labindia-3000+).  
Drug-excipient compatibility study 
FTIR spectra of pure drugs, polymers used and blends were 
recorded on KBr disk method using Brukers Alpha 
Spectrophotometer with IR solution software to confirm the 
compatibility between drug and excipients. Sample powder 
was thoroughly mixed by triturating with potassium 
bromide in a glass mortar with pestle and compressed into 
disks in a hydraulic press (Techno search Instruments, 
India). FTIR spectra of all the samples were recorded over a 
spectral region from 4700 to 400 cm-1 using 20 scans with 4 
cm-1 resolution. 
Preparation of tablets of PCZ 
Fast dissolving tablets of PCZ were prepared by direct 
compression [7] according to the formulae given in Table 1. 
All the ingredients were passed through # 60 mesh 
separately. Then the ingredients were weighed and mixed in 
geometrical order and compressed into tablets of 150 mg 
using 8 mm round flat punches on 10-station rotary tablet 
machine.
 
Table 1 Composition of PCZ fast dissolving tablets 
Ingredients (mg) 
Formulation code 
F1 F2 F3 F4 F5 F6 
Prochlorperazine 
dimaleate 25 25 25 25 25 25 
Sodium Starch glycolate 10 20 - - - - 
Croscarmellose sodium _ _ 10 20 - - 
Crospovidone - - - - 10 20 
Mannitol 10 10 10 10 10 10 
Microcrystalline 
cellulose 94 84 94 84 94 84 
Talc 5 5 5 5 5 5 
Magnesium stearate 6 6 6 6 6 6 
Total weight 150 150 150 150 150 150 
 
Evaluation of fast dissolving tablets of PCZ 
Precompression parameters 
Angle of repose (θ) 
The frictional forces in a loose powder or granules can be 
measured by the angle of repose. This is the maximum angle 
possible between the surface of a pile of powder or granules 
and the horizontal plane. 
Tan θ = h/r 
θ = tan-1 (h/r) 
Where, θ is the angle of repose, h is the height, r is the 
radius. 
The granules were allowed to flow through the funnel fixed 
to a stand at definite height. The angle of repose was then 
calculated by measuring the height and radius of the heap of 
granules formed. 
Bulk density 
Both loose bulk density (LBD) and tapped bulk density 
(TBD) were determined. Accurately weighed amount of 
granules taken in a 50 ml capacity measuring cylinder was 
tapped for 100 times on a plane hard wooden surface and 
estimated the LBD and TBD, calculated by using following 
formulas.  
LBD (Loose Bulk Density) = Mass of Powder/Volume of 
Packing 
TBD (Tapped Bulk Density) = Mass of Powder/Tapped 
Volume of Packing 
Compressibility index 
 The compressibility index of the granules was determined 
by Carr’s compressibility index. 
Carr’s index (%) = [(TBD – LBD)/TBD] × 100. 
Hausner’s ratio 
Hausner’s ratio is an indirect index of ease of measuring the 
powder flow. It was calculated by the following formula [8]. 
Hausner’s ratio = Tapped density/Bulk density. 
Evaluation of Tablets 
Thickness 
Twenty tablets from the representative sample were 
randomly taken and individual tablet thickness was 
measured by using digital vernier caliper [9]. 
Hardness 
Tablet hardness was measured by using Monsanto hardness 
tester. From each batch six tablets were measured for the 
hardness and average of six values was noted along with 
standard deviations. 
Friability Test 
From each batch, ten tablets were accurately weighed and 
placed in the friability test apparatus (Roche friabilator). 
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Apparatus was operated at 25 rpm for 4 minutes and tablets 
were observed while rotating. The tablets were then taken 
after 100 rotations, de dusted and reweighed. The friability 
was calculated as the percentage weight loss. 
% friability was calculated as follows 
% Friability = (W1 – W2) x 100/W1 
Where W1 = Initial weight of the 10 tablets, W2 = Final 
weight of the 10 tablets after testing. 
Friability values below 0.5-1% are generally acceptable. 
Weight Variation Test 
To study weight variation individual weights (WI) of 20 
tablets from each formulation were noted using electronic 
balance. Their average weight (WA) was calculated. Percent 
weight variation was calculated as follows. Average weights 
of the tablets along with standard deviation values were 
calculated. 
Drug content  
The test is mandatory for tablets with 10 mg or less weight 
of active ingredient. Ten randomly selected tablets from 
each formulation (F1 to F6) were finely powdered and Drug 
equivalent  to  10  mg of drug dissolved in 10 ml  phosphate 
buffer pH 6.8 sonicate it for 20 minutes,  till  the  entire  drug 
leached  out  from  complex,  then  the  solution was  filtered  
through  whatman  filter  paper No. 41. From this solution 
take 1 ml and diluted up to 100 ml with phosphate buffer pH 
6.8 and the drug content was determined 
spectrophotometrically at 256 nm. 
In vitro disintegration time 
The disintegration test was performed using an USP 
disintegration apparatus, with distilled water at 24±0.50C. 
The time reported to obtain complete disintegration of six 
tablets were recorded and average was reported. 
Dissolution rate studies 
The prepared tablets were evaluated for in vitro drug 
release. The drug release studies were carried out using USP 
XXII paddle type Dissolution test apparatus. A tablet placed 
in dissolution media (900 ml) which was stirred at 75 rpm 
maintained at 37±0.2C. Samples were withdrawn at 
different time interval and compensated with same amount 
of fresh dissolution medium. Volume of sample withdrawn 
was made up to 10ml Phosphate buffer pH 6.8. The samples 
withdrawn were assayed spectrophotometrically at 256.0 
nm using UV visible spectrophotometer. The release of drug 
was calculated with the help of standard curve of PCZ [10, 
11]. 
RESULTS AND DISCUSSION 
Solubility of PCZ was freely soluble in methanol, sparingly 
soluble in chloroform, soluble in water, 0.1N HCL, 0.1N 
NaOH and 6.8 pH phosphate buffers. The λ max of PCZ was 
found to be 256 nm by using U.V. spectrophotometer 
(Labindia-3000+) in linearity range 2-10 µg/ml Fig.1& 2. 
Tablet powder blend was subjected to various pre-
compression parameters Table 2. The angle of repose values 
indicates that the powder blend has good flow properties. 
The bulk density, tapped density, compressibility index and 
Hauser’s ratio of all the formulations was found to be within 
the range and showing that the powder has well flow 
properties. The results of post-compression parameters 
such as the uniformity of weight, hardness, thickness, 
friability and drug content of the tablets are given in Table 3. 
All the tablets of different batches complied with the official 
requirements of uniformity of weight. The hardness of the 
tablets ranged from 3.4±0.2 to3.6±0.2kg/cm2 and the 
friability values were less than 0.9% indicating that the 
tablets were compact and hard. The thickness of the tablets 
ranged from 2.2 to 2.5 mm. All the formulations satisfied the 
content of the drug as they contained 99.12 to 99.85 % of 
PCZ and good uniformity in drug content was observed. 
Thus all the physical attributes of the prepared tablets were 
found be practically within control. The result in vitro 
disintegration were within the prescribe limit and comply 
with the criteria for orally disintegrating tablets. The tablets 
were evaluated for in vitro dissolution studies in phosphate 
buffer pH 6.8 for 10 min. The results of the optimized 
formulation F5 showed maximum drug release i.e. 98.89 % 
at the end of 10 min. The results of release studies of 
formulations F5 was shown in Table 4. The in vitro drug 
release data of the optimized formulation F5 was subjected 
to goodness of fit test by linear regression analysis according 
to zero order, first order kinetic equation, Higuchi’s and 
Korsmeyer’s models in order to determine the mechanism of 
drug release. When the regression coefficient values of were 
compared, it was observed that ‘r’ values of first order was 
maximum i.e. 1.000 hence indicating drug release from 
formulations was found to follow first order kinetics Table 5 
& Fig. 3-6.  
 
Figure 1 Determination of λmax of PCZ 
 
Figure 2 Calibration curve of PCZ at 256 nm
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Table 2 Results of pre-compression parameters of PCZ 
Formulation 
code 
Parameters 
Bulk 
density(gm/ml) 
Tapped bulk 
density(gm/ml) 
Carr’s Index 
(%) 
Hausner’s 
Ratio 
F1 0.415 0.521 20.345 1.255 
F2 0.426 0.529 19.471 1.242 
F3 0.432 0.542 20.295 1.255 
F4 0.436 0.541 19.409 1.241 
F5 0.439 0.548 19.891 1.248 
F6 0.438 0.542 19.188 1.237 
 
Table 3 Results of Post-Compression parameters of all formulations 
F. Code Hardness 
(kg/cm2)* 
Friability 
(%)* 
 
Weight  
variation 
(%)* 
Thickness 
(mm)* 
 
Drug content 
(%)* 
 
Disintegration 
Time (sec.)* 
Mean ± SD 
F1 3.4±0.2 0.856±0.045 155±3 2.2±0.2 99.85±0.45 120±5 
F2 3.5±0.3 0.845±0.012 154±4 2.3±0.1 99.65±0.25 85±4 
F3 3.6±0.2 0.658±0.25 150±2 2.4±0.3 99.78±0.45 110±2 
F4 3.5±0.1 0.896±0.032 148±5 2.2±0.1 99.45±0.65 75±6 
F5 3.4±0.3 0.754±0.054 146±6 2.5±0.4 99.15±0.23 65±5 
F6 3.5±0.4 0.754±0.045 153±4 2.4±0.2 99.12±0.41 112±3 
*Average of three determinations (n=3) 
Table 4 In-vitro drug release data for optimized formulation F5 
Time 
(min) 
Square Root of 
Time(h)1/2 
Log Time 
Cumulative*% Drug 
Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative 
% Drug 
Remaining 
2 1.414 0.301 48.85 1.689 51.15 1.7088 
5 2.236 0.699 75.65 1.879 24.35 1.3865 
10 3.162 1.000 98.89 1.995 1.11 0.0453 
 
Table 5 Regression analysis data  
Batch 
Zero Order First Order Higuchi Korsmeyer-Peppas 
R² R² R² R² 
F5 0.966 1.000 0.949 0.963 
 
 
Figure 3 Zero order release Kinetics 
 
Figure 4 First order release kinetics 
 
Figure 5 Higuchi release kinetics 
 
Figure 6 Korsmeyer-Peppas release kinetics 
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CONCLUSION 
The oral fast dissolving tablet of PCZ were formulated and 
evaluated for various parameters from the compatibility 
studies by IR of drug it was found to be compatible with 
other formulation excipients. All evaluation parameter were 
within specification. The crospovidone shown faster drug 
release than sodium starch glycolate and crosscarmellose 
sodium. Formulation F5 release maximum drug within the 
10mins.ie. 98.89 % and shown minimum disintegration time 
i.e. 65 sec than other formulation and hence considered best 
formulation. 
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